

Financial news for RGEN dated on 2020-05-27: Stifel Maintains Buy on Repligen, Raises Price Target to \$150

Financial news for RGEN dated on 2020-05-26: Regeneron Pharmaceuticals shares are trading lower after Sanofi said it would sell its investment in the company.

Financial news for RGEN dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for RGEN dated on 2020-05-18: Stocks That Hit 52-Week Highs On Monday

Financial news for RGEN dated on 2020-05-15: Stocks That Hit 52-Week Highs On Friday

Financial news for RGEN dated on 2020-05-15: The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO

Financial news for RGEN dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for RGEN dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for RGEN dated on 2020-05-08: The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda

Financial news for RGEN dated on 2020-05-07: Stocks That Hit 52-Week Highs On Thursday

Financial news for RGEN dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500

Financial news for RGEN dated on 2020-05-07: HC Wainwright & Co. Maintains Buy on Repligen, Raises Price Target to \$143

Financial news for RGEN dated on 2020-05-07: SVB Leerink Maintains Outperform on Repligen, Raises Price Target of \$150

Financial news for RGEN dated on 2020-05-06: Why Repligen's Stocks Is Trading Higher Today

Financial news for RGEN dated on 2020-05-06: Stocks That Hit 52-Week Highs On Wednesday

Financial news for RGEN dated on 2020-05-06: Repligen shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for RGEN dated on 2020-05-06: Repligen Reaffirms FY20 Sales Guidance \$309M-\$319M, Raises Adj. EPS Guidance From \$1.07-\$1.12 To \$1.09-\$1.14

Financial news for RGEN dated on 2020-05-06: Repligen Q1 Adj. EPS \$0.320 Beats \$0.210 Estimate, Sales \$76.100M Beat \$71.190M Estimate

Financial news for RGEN dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for RGEN dated on 2020-04-27: Stocks That Hit 52-Week Highs On Monday

Financial news for RGEN dated on 2020-04-24: The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures \$54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO

Financial news for RGEN dated on 2020-04-23: Stocks That Hit 52-Week Highs On Thursday

Financial news for RGEN dated on 2020-04-23: The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt

Financial news for RGEN dated on 2020-04-02: Stifel Maintains Buy on Repligen, Lowers Price Target to \$113

Financial news for RGEN dated on 2020-03-23: HC Wainwright & Co. Maintains Buy on Repligen, Lowers Price Target to \$100

Financial news for RGEN dated on 2020-02-21: Stifel Nicolaus Maintains Buy on Repligen, Raises Price Target to \$116

Financial news for RGEN dated on 2020-02-21: Stephens & Co. Maintains Overweight on Repligen, Raises Price Target to \$114

Financial news for RGEN dated on 2020-02-20: Repligen Sees FY20 Sales \$309M-\$319M Vs. 314.74M Est., EPS \$1.07-\$1.12 Vs. \$1.10 Est.

Financial news for RGEN dated on 2020-02-20: Repligen Q4 EPS \$0.2 Beats \$0.18 Estimate, Sales \$69.5M Beat \$68.37M Estimate

Financial news for RGEN dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for RGEN dated on 2020-02-19: Stocks That Hit 52-Week Highs On Wednesday

Financial news for RGEN dated on 2020-02-19: 24 Stocks Moving in Wednesday's Pre-Market Session

Financial news for RGEN dated on 2020-02-16: The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions

Financial news for RGEN dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for RGEN dated on 2020-02-12: Stocks That Hit 52-Week Highs On Wednesday

Financial news for RGEN dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for RGEN dated on 2020-02-05: Stocks That Hit 52-Week Highs On Wednesday

Financial news for RGEN dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for RGEN dated on 2020-02-04: Stocks That Hit 52-Week Highs On Tuesday

Financial news for RGEN dated on 2020-02-04: The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

Financial news for RGEN dated on 2020-02-03: Stocks That Hit 52-Week Highs On Monday

Financial news for RGEN dated on 2020-01-23: The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment

Financial news for RGEN dated on 2020-01-22: Stocks That Hit 52-Week Highs On Wednesday

Financial news for RGEN dated on 2020-01-22: The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

Financial news for RGEN dated on 2020-01-21: Stocks That Hit 52-Week Highs On Tuesday

Financial news for RGEN dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for RGEN dated on 2020-01-15: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

Financial news for RGEN dated on 2020-01-14: The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

Financial news for RGEN dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for RGEN dated on 2019-11-15: Benzinga's Top Upgrades, Downgrades For November 15, 2019

Financial news for RGEN dated on 2019-11-15: Stifel Nicolaus Initiates Coverage On Repligen with Buy Rating, Announces \$105 Price Target

Financial news for RGEN dated on 2019-11-01: Benzinga's Top Upgrades, Downgrades For November 1, 2019

Financial news for RGEN dated on 2019-11-01: First Analysis Upgrades Repligen to Strong Buy

Financial news for RGEN dated on 2019-10-31: The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

Financial news for RGEN dated on 2019-10-31: Repligen Raises FY19 Sales Guidance From \$264M-\$268M To \$267M-\$270M vs \$266M Estimate, Adj. EPS From \$0.94-\$0.98 To \$1-\$1.04 vs \$0.97 Est.

Financial news for RGEN dated on 2019-10-31: Repligen Q3 Adj. EPS \$0.26 Up From \$0.2 YoY, Sales \$69.4M Up From \$49.529M YoY

Financial news for RGEN dated on 2019-09-10: 84 Biggest Movers From Yesterday

Financial news for RGEN dated on 2019-09-09: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for RGEN dated on 2019-09-09: Mid-Morning Market Update: Markets Mostly Higher; Alcoa To Consolidate Sales, Procurement And Commercial Operations

Financial news for RGEN dated on 2019-08-23: Stephens & Co. Reinstates Overweight on Repligen, Announces \$110 Price Target

Financial news for RGEN dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for RGEN dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for RGEN dated on 2019-08-01: Stocks That Broke Yearly Highs Thursday Morning

Financial news for RGEN dated on 2019-08-01: Repligen Q2 Adj. EPS \$0.31 Beats \$0.25 Estimate, Sales \$70.7M Beat \$63.89M Estimate

Financial news for RGEN dated on 2019-07-31: Stocks That Managed to Breach 52-Week Highs Wednesday Morning

Financial news for RGEN dated on 2019-07-30: The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Financial news for RGEN dated on 2019-07-29: New Equities that Broke Through 52-Week Highs Monday Morning

Financial news for RGEN dated on 2019-07-26: Companies That Achieved 52-Week Highs Friday

Financial news for RGEN dated on 2019-07-26: The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint

Financial news for RGEN dated on 2019-07-22: Benzinga's Top Upgrades, Downgrades For July 22, 2019

Financial news for RGEN dated on 2019-07-22: H.C. Wainwright Upgrades Repligen to Buy

Financial news for RGEN dated on 2019-07-17: Repligen Prices 1.8M Share Common Stock Offering @\$87/Share

Financial news for RGEN dated on 2019-07-15: Repligen shares are trading lower after the company reported a concurrent \$100 million common stock offering and a \$250 million convertible senior notes offering.

Financial news for RGEN dated on 2019-07-15: Repligen Reports Concurrent \$100M Common Stock, \$250M Convertible Senior Notes Offering

Financial news for RGEN dated on 2019-06-28: The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO

Financial news for RGEN dated on 2019-06-21: The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy

Financial news for RGEN dated on 2019-06-20: The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge

Financial news for RGEN dated on 2019-06-19: The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut

Financial news for RGEN dated on 2019-06-06: The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

Financial news for RGEN dated on 2019-06-05: The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache

Financial news for RGEN dated on 2019-05-31: The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

Financial news for RGEN dated on 2019-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for RGEN dated on 2019-05-09: Repligen Raises FY2019 EPS Guidance from \$0.81-0.86 to \$0.84-0.9; Raises FY2019 Sales Guidance from \$218M-225M to \$235M-241M

Financial news for RGEN dated on 2019-05-09: Repligen Q1 EPS \$0.28 Beats \$0.21 Estimate, Sales \$60.6M Beat \$52.86M Estimate

Financial news for RGEN dated on 2019-05-01: Repligen shares are trading lower after the company priced a 2.7M share stock offering at \$64 per share.

Financial news for RGEN dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for RGEN dated on 2019-05-01: Repligen Prices 2.7M Share Offering @\$64/Share

Financial news for RGEN dated on 2019-04-30: The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

Financial news for RGEN dated on 2019-04-29: Repligen Reports \$175M Common Stock Offering

Financial news for RGEN dated on 2019-04-29: 48 Biggest Movers From Friday

Financial news for RGEN dated on 2019-04-26: Repligen shares are trading higher after the company entered into an agreement to acquire C Technologies for \$240 million; \$192 million in cash and \$48 million in common stock.

Financial news for RGEN dated on 2019-04-26: Repligen Earlier Issued Preliminary Q1 Results; Sees Q1 Adj. EPS \$0.27-\$0.28 vs \$0.20 Est., Sales \$60M-\$61M vs \$55.78M Est.

Financial news for RGEN dated on 2019-04-26: Repligen Earlier Announced It Will Acquire C Technologies For \$240M

Financial news for RGEN dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for RGEN dated on 2019-02-21: Repligen Corporation Sees FY19 Adj. EPS \$0.81-\$0.86 vs \$0.85 Est., Sales \$218M-\$225M vs \$217.25M Est.

Financial news for RGEN dated on 2019-02-21: Repligen Q4 Adj. EPS \$0.21, Inline, Sales \$51.942M Beat \$50.4M Estimate

Financial news for RGEN dated on 2019-02-21: The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan

Financial news for RGEN dated on 2018-11-26: Rocket Pharmaceuticals And REGENXBIO Announce New License Agreement For The Treatment Of Danon Disease Using NAV AAV9 Vector; REGENXBIO Grants Rocket Exclusive Worldwide Rights To NAV AAV9 And In Return Will Receive \$7M Upfront Payment

Financial news for RGEN dated on 2018-11-08: Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018

Financial news for RGEN dated on 2018-11-02: JP Morgan Maintains Overweight on Repligen, Raises Price Target to \$70

Financial news for RGEN dated on 2018-11-02: The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug

Financial news for RGEN dated on 2018-11-02: 76 Biggest Movers From Yesterday

Financial news for RGEN dated on 2018-11-01: Repligen shares are up 16.7% after the company beat Q3 earnings estimates and raised FY18 guidance.

Financial news for RGEN dated on 2018-11-01: Repligen Raises FY18 Adj. EPS Guidance From \$0.69-\$0.73 To \$0.71-\$0.75 vs \$0.71 Estimate, Sales From \$185M-\$190M To \$191M-\$194M vs \$187.9M Est.

Financial news for RGEN dated on 2018-11-01: Repligen Corporation Q3 EPS \$0.20 Beats \$0.18 Estimate, Sales \$49.5M Beat \$46.74M Estimate

Financial news for RGEN dated on 2018-10-05: The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker

Financial news for RGEN dated on 2018-09-26: Benzinga's Top Upgrades, Downgrades For September 26, 2018

Financial news for RGEN dated on 2018-09-26: H.C. Wainwright Initiates Coverage On Repligen with Neutral Rating, Announces \$49 Price Target

Financial news for RGEN dated on 2018-09-17: Stocks Which Set New 52-Week High Friday, September 14th

Financial news for RGEN dated on 2018-09-10: Stocks Which Set New 52-Week High Friday, September 7th

Financial news for RGEN dated on 2018-09-07: Stocks That Made New 52-Week Highs Yesterday, September 6th

Financial news for RGEN dated on 2018-09-07: The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering

Financial news for RGEN dated on 2018-09-06: Stocks Which Set New 52-Week High Yesterday, September 5th

Financial news for RGEN dated on 2018-09-06: The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data

Financial news for RGEN dated on 2018-09-05: Stocks Which Set New 52-Week High Yesterday, September 4th

Financial news for RGEN dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for RGEN dated on 2018-09-04: Repligen Shares Unaffected Following Press Release Highlighting Partnership With Sartorius Stedim Biotech For Introduction Of Next-Gen Perfusion-Enabled Bioreactors, No Terms Disclosed

Financial news for RGEN dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for RGEN dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for RGEN dated on 2018-08-30: Stocks Which Set New 52-Week High Yesterday, August 29th

Financial news for RGEN dated on 2018-08-30: The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration

Financial news for RGEN dated on 2018-08-29: The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent

Financial news for RGEN dated on 2018-08-27: Stocks Which Set New 52-Week High Friday, August 24th

Financial news for RGEN dated on 2018-08-24: Stocks Which Set New 52-Week High Yesterday, August 23rd

Financial news for RGEN dated on 2018-08-24: The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict

Financial news for RGEN dated on 2018-08-23: Stocks Which Set New 52-Week High Yesterday, August 22nd

Financial news for RGEN dated on 2018-08-23: The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero

Financial news for RGEN dated on 2018-08-22: Stocks Which Set New 52-Week High Yesterday, August 21st

Financial news for RGEN dated on 2018-08-22: The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin

Financial news for RGEN dated on 2018-08-21: Stocks Which Set New 52-Week High Tues., Aug. 21, 2018

Financial news for RGEN dated on 2018-08-10: Stocks Which Set New 52-Week High Yesterday, August 9th

Financial news for RGEN dated on 2018-08-08: Stocks Which Set New 52-Week High Yesterday, August 7th

Financial news for RGEN dated on 2018-08-02: Repligen Sees FY18 Adj. EPS \$0.69-\$0.73 vs \$0.71 Est., Sales \$185M-\$190M vs \$185.35M Est.

Financial news for RGEN dated on 2018-08-02: Repligen Q2 EPS \$0.16 Misses \$0.18 Estimate, Sales \$47.7M Beat \$46.08M Estimate

Financial news for RGEN dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for RGEN dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for RGEN dated on 2018-07-25: Stocks Which Set New 52-Week High Yesterday, July 24th:

Financial news for RGEN dated on 2018-07-20: Stocks Which Set New 52-Week High Yesterday

Financial news for RGEN dated on 2018-07-06: Benzinga's Daily Biotech Pulse: Biogen And Eisai's Alzheimer's Drug Meets End Points In Mid-Stage Trial, Obseva To List Shares On Swiss Exchange

Financial news for RGEN dated on 2018-06-27: Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading

Financial news for RGEN dated on 2018-06-27: UPDATE: Repligen Says Co., Navigo Will Co Develop Portfolio Of Next-Gen Ligands Utilizing Navigo's Proprietary Precision Capturing Technology Platform; Repligen To Receive IP Rights, Exclusivity, But No Further Terms Disclosed

Financial news for RGEN dated on 2018-06-27: Repligen Reports Deal With Navigo Proteins For Advancement Of Exclusive Novel Affinity Ligands United In Monoclonal Antibody, Non-Monoclonal Antibody Downstream Purification Processes

Financial news for RGEN dated on 2018-05-08: Repligen Raises FY2018 EPS Guidance from \$0.68-0.72 to \$0.69-0.73 vs \$0.70 Est; Raises FY2018 Sales Guidance from \$180.0M-186.0M to \$182.0M-188.0M vs \$183.50M Est

Financial news for RGEN dated on 2018-05-08: Repligen Q1 EPS \$0.17 Beats \$0.15 Estimate, Sales \$44.83M Beat \$43.93M Estimate

Financial news for RGEN dated on 2018-03-20: Repligen Reports Market Launch Of OPUS 80R

Financial news for RGEN dated on 2018-02-23: 56 Biggest Movers From Yesterday

Financial news for RGEN dated on 2018-02-22: 45 Stocks Moving In Thursday's Mid-Day Session

Financial news for RGEN dated on 2018-02-22: Repligen Sees FY18 Sales \$180-\$186M vs \$184M Est., EPS \$0.68-\$0.72 vs \$0.72 Est.

Financial news for RGEN dated on 2018-02-22: Repligen Reports Q4 Adj. EPS \$0.20 vs \$0.12 Est., Sales \$41.6M vs \$41.1M Est.

Financial news for RGEN dated on 2017-12-08: Citigroup Initiates Coverage On Repligen with Buy Rating, Announces \$45.00 Price Target

Financial news for RGEN dated on 2017-12-08: Benzinga's Top Upgrades, Downgrades For December 8, 2017

Financial news for RGEN dated on 2017-12-05: Benzinga's Top Upgrades, Downgrades For December 5, 2017

Financial news for RGEN dated on 2017-12-05: JP Morgan Initiates Coverage On Repligen with Overweight Rating, Announces \$42.00 Price Target

Financial news for RGEN dated on 2017-11-13: CL King Initiates Coverage On Repligen with Buy Rating, Announces \$41.00 Price Target

Financial news for RGEN dated on 2017-11-09: Repligen Raises FY17 Adj. EPS Guidance From \$0.57-\$0.62 To \$0.60-\$0.63 vs \$0.59 Est.

Financial news for RGEN dated on 2017-11-09: Repligen Narrows FY17 Sales Outlook From \$138M-\$144M To \$139M-\$142M vs \$140.6M Est.

Financial news for RGEN dated on 2017-11-09: Repligen Reports Q3 Adj. EPS \$0.15 vs \$0.11 Est., Sales \$36.6M vs \$35.3M Est.

Financial news for RGEN dated on 2017-11-07: Repligen Extends Long Term Supply Agreement with Purolite for Protein A Ligands, Terms Not Disclosed

Financial news for RGEN dated on 2017-09-26: Mid-Afternoon Market Update: Ascena Retail Climbs Following Strong Earnings; Axovant Sciences Shares Plunge

Financial news for RGEN dated on 2017-09-26: Jefferies Analyst Earlier Commented On GE Healthcare's Launch Of Protein A Resin: Near-Term Impact On Repligen Will Be Negligible, But Long-Term Impact Will Be Negative

Financial news for RGEN dated on 2017-09-26: Stephens Analyst Earlier Commented On Downside In Repligen Shares: Classifies GE Healthcare's Protein A Resin As 'Niche,' Doesn't See Driving Material Sales For At Least 5 Years; Says Repligen's Sales From GE Will Not Be Impacted, Cites Long-Term Contract

Financial news for RGEN dated on 2017-09-26: 15 Biggest Mid-Day Losers For Tuesday

Financial news for RGEN dated on 2017-09-26: Repligen Shares Down 15% Tuesday Amid Concern Related To Monday Launch Of GE Healthcare's New Protein A Chromatography Resin, Continued Investment Into Resin

Financial news for RGEN dated on 2017-08-21: Roy T. Eddleman Reports 11% Passive Stake In Repligen Corp as of August 1, 2017 -13G

Financial news for RGEN dated on 2017-08-03: Repligen Reports Q2 Adj. EPS \$0.20 vs \$0.15 Est., Sales \$32.5M vs \$31.5M Est.

Financial news for RGEN dated on 2017-08-01: Repligen Shares Spike ~\$0.60 Over Last Min., Now Up 2.1% For Session

Financial news for RGEN dated on 2017-06-27: Repligen Prices~2.897M Share Offering @\$42.75/Share

Financial news for RGEN dated on 2017-06-26: Repligen Announces \$15M Offering Common Stock

Financial news for RGEN dated on 2017-06-23: A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Fed Speakers, Economic Data

Financial news for RGEN dated on 2017-06-23: Repligen Reports Deal To Buy Privately-Held Spectrum For ~\$359M

Financial news for RGEN dated on 2017-06-23: Repligen Shares Halted News Pending

Financial news for RGEN dated on 2017-05-04: Repligen Reports Q1 Adj. EPS \$0.15 vs \$0.13 Est., Sales \$30.6M vs \$29.6M Est.

Financial news for RGEN dated on 2017-04-24: First Analysis Initiates Coverage On Repligen with Equal-Weight Rating, Announces \$40.00 Price Target

Financial news for RGEN dated on 2017-03-20: PreMarket Prep Recap, March 20: Major Volatility At Friday's Close And Why Disney Is In For A Big Quarter

Financial news for RGEN dated on 2017-02-22: Repligen Sees FY17 Sales \$121-\$126M vs. \$123M Est., Adj. EPS \$0.54-\$0.59 vs. \$0.55 Est.

Financial news for RGEN dated on 2017-02-22: Repligen Reports Q4 EPS \$0.15 vs. \$0.07 Est., Sales \$25.59M vs. \$24.05M Est.

Financial news for RGEN dated on 2016-12-15: Repligen Acquires TangenX Technology for EUR \$37M

Financial news for RGEN dated on 2016-11-17: 10 Stocks That Rallied Four Days, Then

Sold Off Yesterday

Financial news for RGEN dated on 2016-11-03: Repligen Reports Q3 EPS \$0.08 vs. Est. \$0.08, Rev. \$24.7M vs. Est. \$24.3M

Financial news for RGEN dated on 2016-09-09: 15 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for RGEN dated on 2016-08-04: Repligen Sees FY16 Rev. \$101-\$105M vs. Est. \$99.45M, EPS \$0.42-\$0.48 vs. Est. \$0.47

Financial news for RGEN dated on 2016-08-04: Repligen Reports Q2 Adj. EPS \$0.16 vs. Est. \$0.13, Rev. \$29.2M vs. Est. \$24.7M

Financial news for RGEN dated on 2016-05-19: Mid-Afternoon Market Update: Stage Stores Drops On Downbeat Results; Urban Outfitters Shares Surge

Financial news for RGEN dated on 2016-05-18: Filing from Repligen Showed Registration for Mixed Securities Shelf Offering

Financial news for RGEN dated on 2016-05-05: Repligen Sees FY16 Sales \$98M-\$102M vs \$96.8M Est., Adj. EPS \$0.45-\$0.51 vs \$0.43 Est.

Financial news for RGEN dated on 2016-05-05: Repligen Reports Q1 Adj. EPS \$0.12 vs \$0.10 Est., Sales \$25.1M vs \$22.5M Est.

Financial news for RGEN dated on 2016-04-04: Benzinga's M&A Chatter for Monday April 4, 2016

Financial news for RGEN dated on 2016-04-04: Repligen Acquires Atoll GmbH For \$22.5M, \$9.1M Cash And 538K Shares Of Repligen Stock

Financial news for RGEN dated on 2016-03-16: Morgan Stanley Speculates RGEN EPS Impact If Found To Pay Royalties To AMGN; A 5% Royalty Rate Would Negatively Impact EPS ~1-2% Btwn 2017-2020, A 15% Rate Impacts EPS ~3-6%, A 25% Rate Impacts EPS ~5-10%

Financial news for RGEN dated on 2016-02-25: Repligen Sees FY16 Sales \$93M-\$96M vs \$93.6M Est., Net Income \$15M-\$17M, EBITDA \$25M-\$27M

Financial news for RGEN dated on 2016-02-25: Repligen Reports Q4 Adj. EPS \$0.07, Inline, Sales \$21.4M vs \$19.8M Est.

Financial news for RGEN dated on 2016-02-22: Benzinga's Top Initiations

Financial news for RGEN dated on 2016-02-22: Craig-Hallum Initiates Coverage on Repligen at Buy

Financial news for RGEN dated on 2016-01-21: Mid-Afternoon Market Update: Crude Oil Surges Over 4%; Alkermes Shares Slide Following Announcement of Failed Depression Drug Trial

Financial news for RGEN dated on 2016-01-20: 8 Stocks Moving In Wednesday's After-Hours Session

Financial news for RGEN dated on 2016-01-20: Mid-Afternoon Market Update: Dow Falls Over 400 Points; Advanced Micro Devices Shares Drop After Disappointing Guidance

Financial news for RGEN dated on 2015-12-30: Why These Four Stocks Are Moving In Wednesday's After-Hours Session

Financial news for RGEN dated on 2015-11-17: Mid-Afternoon Market Update: Dicks Sporting Goods Slips On Earnings Miss; Airgas Shares Spike Higher

Financial news for RGEN dated on 2015-11-05: Repligen Sees FY15 Sales \$81M-\$83M vs \$80.2M Est.

Financial news for RGEN dated on 2015-11-05: Repligen Reports Q3 EPS \$0.08, Inline, Sales \$19.8M vs \$20.5M Est.

Financial news for RGEN dated on 2015-09-24: Wednesday's After-Hours Movers: 10 Stocks To Watch

Financial news for RGEN dated on 2015-09-15: Repligen Appoints Glenn P. Muir to Board of Directors

Financial news for RGEN dated on 2015-08-06: Repligen Reports Q2 Product Sales \$21.5M vs \$20.1M Est., EPS \$0.11 vs \$0.08 Est.; Sees FY15 Sales \$78M-\$82M vs \$77.5M Est.

Financial news for RGEN dated on 2015-07-24: Regeneron Approval For Praluent To Treat



## High Cholesterol

Financial news for RGEN dated on 2015-05-07: Repligen Reports Q1 EPS \$0.09 vs \$0.07 Est., Sales \$20.8M vs \$18.2M Est.; Raises FY15 Sales Guidance from \$72M-\$75M to \$75M-\$78M vs \$73.3M Est.

Financial news for RGEN dated on 2015-03-20: Chardan Capital Initiates Coverage on Regeneron at Buy, Announces \$560.00 PT

Financial news for RGEN dated on 2015-03-13: Repligen Reports Q4 EPS -\$0.01 Vs Est +\$0.04, Sales \$16.4M Vs Est \$14.70M

Financial news for RGEN dated on 2015-01-21: Repligen Names Tony Hunt as CEO

Financial news for RGEN dated on 2015-01-08: Repligen Sees FY2015 Sales \$69.0M-72.0M vs \$70.30M Est

Financial news for RGEN dated on 2015-01-08: Repligen Reports Prelim. FY2014 Sales \$63.0M-63.50M vs \$61.0M Est

Financial news for RGEN dated on 2015-01-08: Repligen Announces \$1M Milestone Payment From Pfizer

Financial news for RGEN dated on 2015-01-06: CORRECTION: Barclays Initiates Coverage on Regeneron at Equal-weight, Announces \$450.00 PT

Financial news for RGEN dated on 2014-11-20: Repligen Corp CEO Herlihy Sells 51,386 Shares @\$23.43/Share -Form 4

Financial news for RGEN dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for RGEN dated on 2014-11-06: Repligen Corporation Reports Q3 EPS of \$0.04, Inline; Revenue of \$15.30M vs \$15.60M Est

Financial news for RGEN dated on 2014-10-16: Regeneron Genetics Center Fully Operational, Announces New Collaborations And Key Appointments

Financial news for RGEN dated on 2014-09-29: Option Alert: Repligen Oct \$22.5 Call; 2,450 Contract Traded Near Ask @\$0.15; Currently \$19.11

Financial news for RGEN dated on 2014-09-26: Nike Jumps On Strong Results; Powell Industries Shares Slide

Financial news for RGEN dated on 2014-08-18: Option Alert: Repligen Oct \$22.5 Call; 2,731 Contracts Traded vs 0 OI; Currently \$19.69

Financial news for RGEN dated on 2014-08-11: Repligen Corporation Raises FY2014 Sales Guidance from \$58.0M-61.0M to \$59.0M-62.0M vs \$60.10M Est

Financial news for RGEN dated on 2014-08-11: Repligen Corporation Reports Q2 EPS of \$0.09 vs \$0.06 Est; Revenue of \$15.60M vs \$14.85M Est

Financial news for RGEN dated on 2014-08-11: Earnings Scheduled For August 11, 2014

Financial news for RGEN dated on 2014-07-15: Repligen Hires Jon K. Snodgres As CFO

Financial news for RGEN dated on 2014-07-14: 2 Biotech Stocks That Crushed On Earnings

Financial news for RGEN dated on 2014-06-26: Stocks Hitting 52-Week Highs

Financial news for RGEN dated on 2014-06-03: UPDATE: Repligen Corporation Raises FY2014 Sales Guidance from \$52.0M-55.0M to \$56.0M-59.0M vs \$56.20M Est

Financial news for RGEN dated on 2014-06-03: Repligen Buys Refine Technology for \$20.5Min Cash, 215,285 Shares, Deal Includes Milestone Payment for Up to \$8.75M

Financial news for RGEN dated on 2014-05-08: Repligen Corporation Sees Q1 Sales \$54.0M-57.0M vs \$55.22M Est

Financial news for RGEN dated on 2014-05-08: Repligen Corporation Reports Q1 EPS of \$0.13 vs \$0.09 Est; Revenue of \$16.30M vs \$15.30M Est

Financial news for RGEN dated on 2014-04-15: Repligen Will Replace Hi-Tech Pharmacal in S&P SmallCap 600

Financial news for RGEN dated on 2014-04-15: Mid-Morning Market Update: Markets Gain; Johnson & Johnson Profit Beats Street View

Financial news for RGEN dated on 2014-04-15: Jefferies Initiates Coverage on Repligen Corporation at Buy, Announces \$17.00 PT

Financial news for RGEN dated on 2014-03-26: UPDATE: Repligen Launches OPUS(R) Ready-to-Use Chromatography Columns With Largest Capacity Available on the Market

Financial news for RGEN dated on 2014-03-26: Repligen Unveils OPUS(R) Ready-to-Use Chromatography Columns with Largest Capacity on Market

Financial news for RGEN dated on 2014-03-06: Benzinga's Top #PreMarket Losers

Financial news for RGEN dated on 2014-03-06: Repligen Corporation Sees FY2014 Sales \$54.0M-57.0M

Financial news for RGEN dated on 2014-03-06: Repligen Corporation Reports Q4 EPS of \$0.10 vs \$0.14 Est; Revenue of \$15.40M vs \$15.88M Est

Financial news for RGEN dated on 2014-01-21: BioMarin Confirms Deal with Repligen for HDACI Portfolio, Will Pay \$2M Upfront

Financial news for RGEN dated on 2014-01-21: Repligen Announces Asset Buy Deal with BioMarin for HDACI Portfolio, Will Receive Upfront Payment of \$2M, Has Potential for Added Milestones of Up to \$160M

Financial news for RGEN dated on 2013-11-07: Repligen Corporation Reports Q3 EPS of \$0.18 vs \$0.13 Est; Revenue of \$18.80M vs \$16.27M Est

Financial news for RGEN dated on 2013-09-04: Repligen Receives First Milestone Payment from Pfizer for Development of Treatment for SMA

Financial news for RGEN dated on 2013-08-01: Stocks Hitting 52-Week Highs

Financial news for RGEN dated on 2013-08-01: Repligen Corporation Raises FY2013 Sales Guidance from \$63.0M-65.0M to \$65.0M-67.0M

Financial news for RGEN dated on 2013-08-01: Repligen Corporation Reports Q2 EPS of \$0.14 vs \$0.10 Est; Revenue of \$13.0M

Financial news for RGEN dated on 2013-07-23: Amended 13D from Ronald Chez on Repligen Showing Reduced Stake from 6.09% to 3%

Financial news for RGEN dated on 2013-05-08: Stocks Hitting 52-Week Highs

Financial news for RGEN dated on 2013-05-02: Repligen Corporation Sees FY2013 Sales \$63.0M-65.0M vs \$56.90M Est

Financial news for RGEN dated on 2013-05-02: Repligen Corporation Reports Q1 EPS of \$0.07 vs \$0.11 Est; Revenue of \$16.50M

Financial news for RGEN dated on 2013-04-08: Stocks Hitting 52-Week Highs

Financial news for RGEN dated on 2013-04-03: Stocks Hitting 52-Week Highs

Financial news for RGEN dated on 2013-03-07: Repligen Sees FY13 Net Income \$18-20M

Financial news for RGEN dated on 2013-03-07: Repligen Corporation Reports Q4 EPS of \$(0.30), Down 400% YOY; Revenue of \$18.80M

Financial news for RGEN dated on 2013-03-07: Earnings Scheduled For March 7, 2013

Financial news for RGEN dated on 2013-01-03: Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Financial news for RGEN dated on 2013-01-03: Repligen Enters Global Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program

Financial news for RGEN dated on 2012-10-26: Repligen Commercial Chief Resigns

Financial news for RGEN dated on 2012-10-04: Robert Baird Raises PT on Repligen from \$150 to \$175

Financial news for RGEN dated on 2012-09-21: From Earlier: Repligen Names Lieber CFO

Financial news for RGEN dated on 2012-09-21: Repligen Names Jonathan I. Lieber CFO

Financial news for RGEN dated on 2012-09-10: Hearing Repligen, Nam Tai Electronics Added to Buy List at Navellier

Financial news for RGEN dated on 2012-09-10: Morning Market Movers

Financial news for RGEN dated on 2012-08-22: Novozymes to Partner With Chemtex to Build US Biofuel Plant

Financial news for RGEN dated on 2012-08-02: Benzinga's Microcap Movers for Thursday August 2, 2012

Financial news for RGEN dated on 2012-07-23: Chez Ronald Reports 9.3% Stake in Repligen, Asks Board to Explore Alternatives

Financial news for RGEN dated on 2012-06-22: Repligen Falls After Receiving Complete Response Letter from FDA

Financial news for RGEN dated on 2012-06-22: Benzinga's Top Pre-Market Losers

Financial news for RGEN dated on 2012-06-22: Financial Breakfast: Morning News Summary for June 22, 2012

Financial news for RGEN dated on 2012-06-22: A Peek Into The Market Before The Trading Starts

Financial news for RGEN dated on 2012-06-22: UPDATE: Repligen: FDA Determined More Clinical Efficacy, Safety Trial Data Will Be Required

Financial news for RGEN dated on 2012-06-22: Repligen Receives Complete Response Letter from FDA for RG1068 NDA

Financial news for RGEN dated on 2012-04-30: Shareholder Ronald L. Chez Comments on Recent Repligen Developments

Financial news for RGEN dated on 2012-04-30: Chez Says Spoke to Repligen Chairperson About Proxy Proposal

Financial news for RGEN dated on 2012-04-26: Benzinga's Microcap Movers for Thursday April 26, 2012

Financial news for RGEN dated on 2012-04-26: Repligen Plummets 40% After FDA Canceled Advisory-Committee Meeting for SecreFlo

Financial news for RGEN dated on 2012-04-26: Repligen Resumes Trading

Financial news for RGEN dated on 2012-04-26: PREVIEW: Repligen to Resume Trading at 10:30am

Financial news for RGEN dated on 2012-04-26: Repligen Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee Meeting

Financial news for RGEN dated on 2012-04-26: Repligen Halted; Pending News

Financial news for RGEN dated on 2012-04-25: Repligen Reports Positive Results From Phase 1 Clinical Trial for Spinal Muscular Atrophy (SMA)

Financial news for RGEN dated on 2012-04-11: Shareholder Says Repligen Corporation Acts to Prevent Proxy Proposal That Would Benefit Investors

Financial news for RGEN dated on 2012-03-23: Repligen Announces FDA Advisory Committee Date for SecreFlo NDA

Financial news for RGEN dated on 2012-03-15: Repligen Initiates Phase 1 Clinical Trial of RG2833 in Patients with Friedreich's Ataxia

Financial news for RGEN dated on 2012-03-05: Repligen Announces Submission of Marketing Authorization Application in EU for SecreFlo(tm) to Improve Pancreatic Imaging in Patients with Pancreatitis

Financial news for RGEN dated on 2012-02-21: Financial Breakfast: Morning News Summary for February 21, 2012

Financial news for RGEN dated on 2012-02-21: Repligen Announces FDA Grant of Priority Review for SecreFlo NDA

Financial news for RGEN dated on 2011-12-21: Repligen Announces Submission of New Drug Application for SecreFlo for Improved Pancreatic Imaging In Patients with Pancreatitis

Financial news for RGEN dated on 2011-10-27: PREVIEW: Repligen to Resume Trading at 6pm

Financial news for RGEN dated on 2011-10-27: Repligen Acquires Novozymes BioPharma

for \$22.7M Plus Future Payments

Financial news for RGEN dated on 2011-10-27: Repligen Halted; Pending News

Financial news for RGEN dated on 2011-09-02: Regeneron Up Over 5% After the FDA Announced that Competitor Roche's Avastin Caused Eye Infections

Financial news for RGEN dated on 2011-07-21: Repligen Announces Initiation of RG1068 Pilot Study to Improve Identification and Characterization of Pancreatic Cancer

Financial news for RGEN dated on 2011-07-15: Karen A. Dawes Elected as Repligen Co-chairperson of the Board of Directors

Financial news for RGEN dated on 2011-07-13: Wednesday's Put/Call Ratio Leaders

Financial news for RGEN dated on 2011-07-13: Ronald L. Chez Discloses 8.4% Stake in RepliGen

Financial news for RGEN dated on 2011-06-23: Repligen Receives U.S. Fast Track Designation and European Orphan Medicinal Product Recommendation for RG3039 for Spinal Muscular Atrophy

Financial news for RGEN dated on 2011-06-09: Earnings Scheduled For June 9

Financial news for RGEN dated on 2011-06-01: Repligen Concludes Pre-NDA Meeting with FDA for RG1068

Financial news for RGEN dated on 2011-05-19: Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA

Financial news for RGEN dated on 2011-05-19: Repligen Receives FDA Approval to Initiate Phase 1 Clinical Trial of Potential Treatment for Spinal Muscular Atrophy

Financial news for RGEN dated on 2011-03-14: Trading Resumes: Repligen (RGEN)

Financial news for RGEN dated on 2011-03-14: Repligen Reports Positive Phase 3 Clinical Trial Results for RG1068 in Pancreatic Imaging

Financial news for RGEN dated on 2011-03-14: Trading Halted: Repligen, News Pending (RGEN)

Financial news for RGEN dated on 2011-03-08: Benzinga's Top Pre-Market NASDAQ Gainers (BSFT, ATRN, RGEN, EMKR)

Financial news for RGEN dated on 2011-03-07: Repligen Phase 2b Results for RG2417 for Bipolar Depression Not Demonstrating Significant Improvement

Financial news for RGEN dated on 2011-01-25: NASDAQ Stocks Hitting 52-Week Highs (XLNX, CWST, RGEN, PFIN)

Financial news for RGEN dated on 2011-01-10: Regeneron Pharma Bloomberg TV Appearance (RGEN)

Financial news for RGEN dated on 2010-12-29: NASDAQ Stocks Hitting 52-Week Highs (IPCM, SRCL, SNIC, RGEN)

Financial news for RGEN dated on 2010-09-30: Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417

Financial news for RGEN dated on 2010-05-27: Benzinga's Top Pre-Market Gainers (AIXG, CENX, NTAP, SMMX, RGEN)

Financial news for RGEN dated on 2009-12-10: Repligen Corp. (RGEN) To Outperform

Financial news for RGEN dated on 2009-12-09: Benzinga's Biggest Losers (PIP, ADAT, KR, SVU, AIB)